ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.00%
US Dollar vs MXN
16.6419
0.12%
Brent Oil
81.94
-0.61%
Bitcoin
69,834.03
-0.42%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. RenovoRx Inc (RNXT)

  7. RenovoRx Inc (RNXT) Noticias

RNXT RenovoRx Inc

1.35
0.00 (0.00%)
Pre Mercado
Última actualización: 06:00:06
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
RenovoRx Inc RNXT NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 1.35 06:00:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.35
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
21/5/202408:00BWPublication of Results of Pre-Clinical Studies Support..
14/5/202408:00BWRenovoRx to Participate in Fireside Chat at the A.G.P...
12/5/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
10/5/202416:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/5/202415:50EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/5/202415:47EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/5/202408:00BWRenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital..
18/4/202407:30BWRenovoRx Regains Compliance with Nasdaq Stockholders’ Equity..
16/4/202407:30BWRenovoRx Highlights Recent Presentation of Clinical Data..
15/4/202407:00BWRenovoRx Closes $11.1 Million Private Placement, Providing..
08/4/202407:30BWRenovoRx Announces $11.1 Million at Market Private Placement
05/4/202407:30BWRenovoRx to Present at the Canaccord Genuity Horizons in..
12/3/202408:00BWRenovoRx to Present at the 36th Annual ROTH Conference on..
08/3/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202415:05BWRenovoRx Highlights Key Leadership Promotions
12/2/202418:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202415:30EDGAR2Form 8-K - Current report
06/2/202407:30BWRenovoRx CEO Issues Letter to Shareholders
30/1/202418:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202417:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/1/202417:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/1/202408:06EDGAR2Form 8-K - Current report
29/1/202407:30BWRenovoRx Closes $6.1 Million Private Placement
23/1/202420:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202420:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202420:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202407:30EDGAR2Form 8-K - Current report
21/12/202307:30BWRenovoRx Engages Oklahoma University (OU) Health as First..
19/12/202307:30BWRenovoRx Announces Clinical Data Abstract at the 2024..
18/12/202315:15EDGAR2Form 8-K - Current report
13/12/202307:31BWRenovoRx Files New International Patent for Novel Targeted..
27/11/202312:23EDGAR2Form DEF 14A - Other definitive proxy statements
17/11/202316:30EDGAR2Form PRE 14A - Other preliminary proxy statements
16/11/202307:35BWRenovoRx Expands Scientific Advisory Board with Appointment..
14/11/202307:30BWRenovoRx Reports Third Quarter 2023 Financial Results and..
13/11/202315:58EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:15EDGAR2Form 8-K - Current report
04/10/202315:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202315:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202307:30BWRenovoRx to Present at the ROTH MKM Healthcare Opportunities..
25/8/202315:15EDGAR2Form 8-K - Current report
17/8/202307:30EDGAR2Form 8-K - Current report
17/8/202307:30BWRenovoRx Reports Second Quarter 2023 Financial Results and..
16/8/202313:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
15/8/202314:57EDGAR2Form NT 10-Q - Notification of inability to timely file Form..
31/7/202307:30BWRenovoRx to Present at the 43rd Annual Canaccord Genuity..
20/7/202307:00BWRenovoRx and Imugene Announce Collaboration to Deliver..

Su Consulta Reciente

NASDAQ
RNXT
RenovoRx
BIT
P1QKC2
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados